Gedeon Richter's Verospiron Receives Marketing Authorization in Russia
The Russian Ministry of Health has granted marketing authorization for Gedeon Richter's Verospiron medication. The drug is intended for the treatment of hypertension and heart failure.
Budapest, Hungary – Gedeon Richter Plc. announced that the Ministry of Health of the Russian Federation has granted marketing authorization for its medication Verospiron. The drug, known internationally as spironolactone, is a potassium-sparing diuretic used for conditions including high blood pressure and heart failure.
The authorization of Verospiron in Russia marks a significant step for Gedeon Richter's global market presence. The medication has previously received approvals for similar therapeutic indications in numerous other countries.
Spironolactone functions as an aldosterone antagonist, impacting kidney function by increasing the excretion of sodium and water while reducing potassium loss from the body. Its efficacy in lowering blood pressure is well-established. The drug is also prescribed for conditions such as liver cirrhosis and other states associated with fluid retention or hypokalemia.
Detailed dosage instructions and contraindications for Verospiron have been outlined as part of the Russian regulatory approval process. Gedeon Richter will proceed with the marketing and distribution of the medication within the Russian market.